Meg Jardine's Publications

About Meg Jardine's Publications

Honorary Professorial Fellow, The George Institute for Global Health
  • Associate Professor, Faculty of Medicine, UNSW Sydney

  • Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

    ESC Heart Failure Date published:

  • Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

    Kidney International Reports Date published:

  • Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

    American Journal of Kidney Diseases Date published:

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    Date published:

  • ANTIPLATELET AGENTS FOR CHRONIC KIDNEY DISEASE: AN UPDATED COCHRANE REVIEW

    Date published:

  • MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL

    Date published:

  • The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

    Diabetes, Obesity and Metabolism Date published:

  • Relationship between measured and prescribed dialysate sodium in haemodialysis: a systematic review and meta-analysis

    Nephrology Dialysis Transplantation Date published:

  • SGLT2 inhibitors may offer benefit beyond diabetes

    Nature Reviews Nephrology Date published:

  • Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years: A cohort study using linked routinely-collected data

    Journal of Clinical & Translational Endocrinology Date published:

  • How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?

    Kidney and Blood Pressure Research Date published:

  • The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

    International Journal of Cardiology Date published:

  • Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2

    Clinical Journal of the American Society of Nephrology Date published:

  • Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

    The Lancet Diabetes & Endocrinology Date published:

  • Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

    Diabetes, Obesity and Metabolism Date published:

  • Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

    Diabetes, Obesity and Metabolism Date published: